摘要 |
PCT No. PCT/SE95/01416 Sec. 371 Date Dec. 18, 1995 Sec. 102(e) Date Dec. 18, 1995 PCT Filed Nov. 27, 1995A compound of formula (II), either as a single enantiomer or in an enantiomerically enriched form <IMAGE> (II) wherein: <IMAGE> and <IMAGE> <IMAGE> (wherein N in the benzimidazole moiety of Het2 means that one of the carbon atoms substituted by any one of R6 to R9 optionally may be exchanged for an unsubstituted nitrogen atom; R1, R2 and R3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl, phenylakoxy; R4 and R4, are the same or different and selected from hydrogen, alkyl, aralkyl; R5 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy; R6 -R9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl or adjacent groups R6 -R9 may complete together with the carbon atoms to which they are attached optionally substituted ring structures; R10 is hydrogen or alkoxycarbonyloxymethyl; R11 is hydrogen or forms an alkylene chain together with R3; R12 and R13 are the same or different and selected from hydrogen, halogen or alkyl) is obtained by stereoselective bioreduction of a compound of formula (II) in racemic form.
|